LENZ Therapeutics Inc

자세한 내용은 LENZ Therapeutics Inc 회사

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

회사 정보

종목 코드 LENZ

회사 이름LENZ Therapeutics Inc

상장일Jun 25, 2021

CEOMr. Evert (Eef) Schimmelpennink

직원 수42

유형Ordinary Share

회계 연도 종료Jun 25

주소- -

도시- -

증권 거래소NASDAQ Global Select Consolidated

국가- -

우편 번호- -

전화- -

웹사이트- -

종목 코드 LENZ

상장일Jun 25, 2021

CEOMr. Evert (Eef) Schimmelpennink

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sun, Aug 24

주주

주주 유형

주주

비율

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.58%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

기타

49.24%

주주

비율

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.58%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

기타

49.24%

주주 유형

주주

비율

Venture Capital

39.10%

Hedge Fund

27.55%

Investment Advisor

23.62%

Investment Advisor/Hedge Fund

13.97%

Individual Investor

2.73%

Research Firm

2.25%

Bank and Trust

0.14%

Pension Fund

0.06%

Insurance Company

0.02%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

2023Q1

205

7.41M

89.08%

-2.37M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

RA Capital Management, LP

4.18M

14.85%

--

May 07, 2025

Alpha Wave Global, LP

3.61M

12.83%

--

Apr 14, 2025

Versant Ventures

3.66M

12.99%

-884.80K

-19.48%

Jun 27, 2025

Ridgeback Capital Management, L.P.

1.95M

6.93%

--

Apr 14, 2025

Paradigm BioCapital Advisors LP

1.42M

5.04%

-92.10K

-6.09%

Apr 14, 2025

The Vanguard Group, Inc.

1.20M

4.25%

+21.02K

+1.79%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.05M

3.73%

-14.66K

-1.38%

Mar 31, 2025

Adage Capital Management, L.P.

537.74K

1.91%

+537.74K

--

Mar 31, 2025

72 Investment Holdings, LLC

1.02M

3.62%

--

Mar 31, 2025

Sectoral Asset Management Inc.

977.25K

3.47%

--

Mar 31, 2025

41.690USD

LENZ Therapeutics Inc

41.690

개요

회사

금융

분석